Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 5
2019 1
2020 1
2021 2
2022 3
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.
Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, Takeda J, Momozawa Y, Best S, Krishnamurthy P, Yoshizato T, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, Nagata Y, Kakiuchi N, Onizuka M, Chiba K, Tanaka H, Kon A, Ochi Y, Nakagawa MM, Okuda R, Mori T, Yoda A, Itonaga H, Miyazaki Y, Sanada M, Ishikawa T, Chiba S, Tsurumi H, Kasahara S, Müller-Tidow C, Takaori-Kondo A, Ohyashiki K, Kiguchi T, Matsuda F, Jansen JH, Polprasert C, Blombery P, Kamatani Y, Miyano S, Malcovati L, Haferlach T, Kubo M, Cazzola M, Kulasekararaj AG, Godley LA, Maciejewski JP, Ogawa S. Makishima H, et al. Among authors: iijima yamashita y. Blood. 2023 Feb 2;141(5):534-549. doi: 10.1182/blood.2022018221. Blood. 2023. PMID: 36322930 Free PMC article.
Phase 2 study of combination chemotherapy with bortezomib in children with relapsed and refractory acute lymphoblastic leukemia.
Miyagawa N, Goto H, Ogawa A, Kikuta A, Kosaka Y, Sekimizu M, Tomizawa D, Toyoda H, Hiramatsu H, Hara J, Mochizuki S, Nakayama H, Yoshimura K, Iijima-Yamashita Y, Sanada M, Ogawa C. Miyagawa N, et al. Among authors: iijima yamashita y. Int J Hematol. 2023 Aug;118(2):267-276. doi: 10.1007/s12185-023-03609-8. Epub 2023 May 1. Int J Hematol. 2023. PMID: 37127801 Clinical Trial.
Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I-II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21).
Sakaguchi H, Umeda K, Kato I, Sakaguchi K, Hiramatsu H, Ishida H, Yabe H, Goto H, Kawahara Y, Yamashita YI, Sanada M, Deguchi T, Takahashi Y, Saito A, Noma H, Horibe K, Taga T, Adachi S; Transplantation and Cellular Therapy Committee of Japanese Childhood Cancer Group. Sakaguchi H, et al. Among authors: yamashita yi. BMJ Open. 2023 Apr 17;13(4):e070051. doi: 10.1136/bmjopen-2022-070051. BMJ Open. 2023. PMID: 37068890 Free PMC article.
High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia.
Tomizawa D, Matsubayashi J, Iwamoto S, Hiramatsu H, Hasegawa D, Moritake H, Hasegawa D, Terui K, Hama A, Tsujimoto SI, Kiyokawa N, Miyachi H, Deguchi T, Hashii Y, Iijima-Yamashita Y, Taki T, Noguchi Y, Koike K, Koh K, Yuza Y, Moriya Saito A, Horibe K, Taga T, Tanaka S, Adachi S. Tomizawa D, et al. Among authors: iijima yamashita y. Leukemia. 2024 Jan;38(1):202-206. doi: 10.1038/s41375-023-02075-9. Epub 2023 Nov 6. Leukemia. 2024. PMID: 37926712 No abstract available.
High IL2RA/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core-binding factor.
Aoki T, Shiba N, Tsujimoto S, Yamato G, Hara Y, Kato S, Yoshida K, Ogawa S, Hayashi Y, Iwamoto S, Taki T, Shimada A, Iijima-Yamashita Y, Horibe K, Tawa A, Taga T, Adachi S, Tomizawa D. Aoki T, et al. Among authors: iijima yamashita y. Pediatr Blood Cancer. 2024 Feb;71(2):e30803. doi: 10.1002/pbc.30803. Epub 2023 Dec 6. Pediatr Blood Cancer. 2024. PMID: 38054691
Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations.
Yasuda T, Sanada M, Kawazu M, Kojima S, Tsuzuki S, Ueno H, Iwamoto E, Iijima-Yamashita Y, Yamada T, Kanamori T, Nishimura R, Kuwatsuka Y, Takada S, Tanaka M, Ota S, Dobashi N, Yamazaki E, Hirose A, Murayama T, Sumi M, Sato S, Tange N, Nakamura Y, Katsuoka Y, Sakaida E, Kawamata T, Iida H, Shiraishi Y, Nannya Y, Ogawa S, Taniwaki M, Asou N, Hatta Y, Kiyoi H, Matsumura I, Horibe K, Mano H, Naoe T, Miyazaki Y, Hayakawa F. Yasuda T, et al. Among authors: iijima yamashita y. Blood. 2022 Mar 24;139(12):1850-1862. doi: 10.1182/blood.2021011921. Blood. 2022. PMID: 34695176 Free article.
Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia.
Hasegawa D, Yoshimoto Y, Kimura S, Kumamoto T, Maeda N, Hara J, Kikuta A, Kada A, Kimura T, Iijima-Yamashita Y, Saito AM, Horibe K, Manabe A, Ogawa C. Hasegawa D, et al. Among authors: iijima yamashita y. Int J Hematol. 2019 Nov;110(5):627-634. doi: 10.1007/s12185-019-02714-x. Epub 2019 Aug 10. Int J Hematol. 2019. PMID: 31401767 Clinical Trial.
Multiplex fusion gene testing in pediatric acute myeloid leukemia.
Iijima-Yamashita Y, Matsuo H, Yamada M, Deguchi T, Kiyokawa N, Shimada A, Tawa A, Takahashi H, Tomizawa D, Taga T, Kinoshita A, Adachi S, Horibe K. Iijima-Yamashita Y, et al. Pediatr Int. 2018 Jan;60(1):47-51. doi: 10.1111/ped.13451. Pediatr Int. 2018. PMID: 29105243
Gemtuzumab Ozogamicin Followed by Unrelated Cord Blood Transplantation With Reduced-intensity Conditioning for a Child With Refractory Acute Promyelocytic Leukemia.
Yamada Y, Osumi T, Kato M, Shioda Y, Kiyotani C, Terashima K, Hayakawa A, Iijima-Yamashita Y, Horibe K, Matsumoto K, Tomizawa D. Yamada Y, et al. Among authors: iijima yamashita y. J Pediatr Hematol Oncol. 2022 May 1;44(4):178-180. doi: 10.1097/MPH.0000000000002404. Epub 2022 Jan 28. J Pediatr Hematol Oncol. 2022. PMID: 35091516
Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan.
Iwafuchi H, Nakazawa A, Sekimizu M, Mori T, Osumi T, Iijima-Yamashita Y, Ohki K, Kiyokawa N, Fukano R, Saito AM, Horibe K, Kobayashi R; Lymphoma Committee and Pathology Committee of the Japanese Pediatric Leukemia/Lymphoma Study Group. Iwafuchi H, et al. Among authors: iijima yamashita y. Hum Pathol. 2021 Oct;116:112-121. doi: 10.1016/j.humpath.2021.07.011. Epub 2021 Aug 4. Hum Pathol. 2021. PMID: 34363798
20 results